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The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the
antiplatelet effects of ticagrelor. However, the dynamic interaction of ticagrelor, the ticagrelor active metabolite (TAM), and MEDI2452,
makes pharmacokinetic (PK) analysis nontrivial and mathematical modeling becomes essential to unravel the complex behavior of
this system. We propose a mechanistic PK model, including a special observation model for post-sampling equilibration, which is
validated and refined using mouse in vivo data from four studies of combined ticagrelor-MEDI2452 treatment. Model predictions of
free ticagrelor and TAM plasma concentrations are subsequently used to drive a pharmacodynamic (PD) model that successfully
describes platelet aggregation data. Furthermore, the model indicates that MEDI2452-bound ticagrelor is primarily eliminated together
with MEDI2452 in the kidneys, and not recycled to the plasma, thereby providing a possible scenario for the extrapolation to humans.
We anticipate the modeling work to improve PK and PD understanding, experimental design, and translational confidence.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 313–323; doi:10.1002/psp4.12089; published online 16 June 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Antiplatelet therapy for the prevention of athero-
thrombotic events in patients with acute coronary syn-
drome is known to increase the risk of bleeding
complications. The unique reversible binding mode of
action of the oral antiplatelet agent, ticagrelor, has
enabled the development of MEDI2542, a ticagrelor-
specific antidote for rare emergency situations.
WHAT QUESTION DOES THIS STUDY ADDRESS?
 This study seeks to unravel the PK interaction between
ticagrelor and MEDI2452 through the use of mathematical
modeling, aiming for both qualitative understanding as
well as detailed quantitative predictions.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 A mathematical model describing the simultaneous
PKs of ticagrelor and MEDI2452 in the mouse is pre-
sented. The model offers a mechanistic explanation for
the complex kinetics and can predict the unobserved
free ticagrelor plasma concentration that drives the pla-
telet aggregation PDs.
HOW THIS MIGHT CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS
 The combined ticagrelor-MEDI2452 model can con-
tribute to the development of MEDI2452 by assisting in
interpretation of observed data, by prediction of free
ticagrelor and TAM plasma concentrations, and by sim-
ulation of experimental designs.
Ticagrelor is a direct acting and reversibly binding P2Y12
antagonist.1 In the PLATO study, a positive benefit-risk profile
for the prevention of atherothrombotic events in patients with
acute coronary syndrome was established.2 Based on the
PLATO data, as well as data with the thienopyridines, clopi-
dogrel in CURE,3 and prasugrel in TRITON,4 dual antiplatelet
therapy, consisting of aspirin and a P2Y12 antagonist, is criti-
cal for the treatment of acute coronary syndrome. In addition,
in the recently completed PEGASUS TIMI-54, the benefit-risk
profile for long-term treatment with ticagrelor in patients with a
history of myocardial infarction and a high risk of developing
an atherothrombotic event was documented supporting the
use of ticagrelor for long-term treatment.5 However, all antipla-
telet therapies are known to increase the risk of bleeding
complications.2–5 The unique reversibly binding mode of
action of ticagrelor provides an opportunity for developing a
specific reversal agent not possible for the thineopyridines,
which are all irreversible P2Y12 antagonists. The first data for
the ticagrelor-specific neutralizing antibody fragment (Fab),
MEDI2452, has recently been published.6
MEDI2452 specifically binds free (unbound to plasma
proteins) ticagrelor and free AR-C124910XX—the ticagrelor
active metabolite (TAM)—with a high affinity of about
20 pM.6,7 MEDI2452 thereby prevents ticagrelor’s and
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TAM’s (similar potency vs. P2Y12 as ticagrelor) interaction
with, and inhibition of, the platelet P2Y12 receptor.
MEDI2452 may prove valuable as an agent for patients on
ticagrelor therapy who require urgent surgery or suffer an
acute major bleed. If successful, MEDI2452 would be the
first antidote for an antiplatelet drug. Recently, specific anti-
dotes for oral anticoagulants have been described and are
undergoing clinical trials, including a specific Fab for the
thrombin inhibitor dabigatran, idarucizumab,8–11 and a
recombinant catalytically inactive Factor (F)Xa, andexanet
alfa, which is targeted to reverse all the FXa inhibitors.12
The main objective of the present work is to better under-
stand the pharmacokinetics (PKs) of ticagrelor, TAM, and
MEDI2452, in general, and to be able to predict free plasma
concentrations of ticagrelor and TAM in particular. Knowledge
of free plasma concentrations is crucial as it is only the free
fractions—and not the more than 99% protein-bound fraction
or the dynamically changing MED2452-bound fraction—that
can inhibit the P2Y12 receptor and thereby drive the pharmaco-
dynamic (PD) response. The PK analysis is complex because
of the dynamic interaction that occurs between these com-
pounds when administered to the same system. It is expected
that mathematical modeling will be essential for unraveling their
combined PK behavior. In addition, we investigate if a simple
turnover model driven by the predicted free levels can describe
PD data of platelet aggregation. The work was accomplished
in three stages. First, a mathematical model of the combined
ticagrelor-MEDI2452 PK in the mouse was set up based on
data of separately administered ticagrelor and MEDI2452, and
on assumptions supported by literature. Second, the model
was validated and refined using several different combined
ticagrelor-MEDI2452 PK datasets not used in the first stage.
Finally, the model was used to understand how the complex
PK emerges from the ticagrelor-MEDI2452 interaction. Specifi-
cally, we let the model predict free plasma levels of ticagrelor
and TAM under different experimental designs, and, in turn, let
these predictions drive the PD model.
MATERIALS AND METHODS
MEDI2452 prestudy: dosing only MEDI2452 to rats
MEDI2452 PK was observed following a 1,000 mg 3 kg21 i.v.
bolus dose in conscious Sprague-Dawley rats. Venous serum
samples were obtained predose and at 5, 15, and 30 minutes,
and 1, 2, 6, 12, 24, and 48 hours postdose. The study was
performed by Huntingdon Life Sciences (Huntingdon, UK) in
compliance with the United Kingdom Animals (Scientific Proce-
dures) Act 1986 Amendment Regulations 2012.
Ticagrelor prestudies: dosing only ticagrelor to mice
Ticagrelor PK in nonfasted male C57Bl6 mice (Charles River,
Sulzfeld, Germany; body weight in the range of 15–25 g) was
observed in two studies, of which the first also included TAM
observations. The studies were approved by the ethical com-
mittee for animal research at the University of G€oteborg, Swe-
den. Mice were anesthetized with isoflurane vapor (Forene;
Abbot Scandinavia AB, Sweden). A catheter was inserted in
the left jugular vein for administration of the vehicle or drug.
The body temperature was maintained at 388C by external
heating. In the first study, four mice were given ticagrelor as an
i.v. infusion at a rate of 240 lg 3 min21 3 kg21 for 5 minutes,
followed by 30 lg 3 min21 3 kg21 for 15 minutes. The tica-
grelor and TAM total concentrations (free and protein-bound) in
plasma were observed at 20, 30, 40, 50, 65, and 80 minutes
after the start of infusion (thus, the first sample was collected
immediately poststop of infusion). In the second study, two
mice were administered an i.v. bolus dose of 2,000 lg 3 kg21
ticagrelor. The total ticagrelor concentration in blood was meas-
ured in samples collected at 2, 5, 10, 30, 60, 90, 120, and 150
minutes after the dose.
Main studies: dosing MEDI2452 to ticagrelor-treated
mice
Four different studies in nonfasted male C57Bl6 mice were
used for model validation and refinement, labeled study 1 to 4.
Their designs are illustrated in Figure 1, and the full details
are given in Supplementary Text S1. Animal handling and
experimental setup were as described for the ticagrelor pre-
studies. In common with these studies, the mice were first
dosed with an i.v. infusion of ticagrelor, allowing the plasma
concentration to reach steady-state. Then, a bolus of the anti-
dote MEDI2452 was administered. The PD data from studies
1, 3, and 4 have previously been reported.6
Bioanalysis
Quantification of total (free and protein bound) as well as free
(protein unbound) ticagrelor and TAM in plasma samples in the
mouse was determined by protein precipitation and liquid chro-
matography mass spectrometry. The lower limits of quantification
of free ticagrelor and TAM were 0.03 nmol L21 and 0.06 nmol
L21. Quantification of MEDI2452 in mouse and rat plasma was
performed with the Gyrolab nanoliter scale immunoassay assay
platform. Mouse and rat assays had lower limits of quantification
of 260 and 350 ng3mL21. Quantification of ADP-induced plate-
let aggregation was evaluated using the Multiplate impedance
aggregometer (Dynabyte, Munich, Germany). Further details of
the bioanalysis are given in Supplementary Text S1.
Data analysis
Parameter estimation was performed according to a maximum
likelihood approach with a multiplicative lognormal error model
for the PK model and a mixed additive and multiplicative
error model for the PD model, using the na€ıve-pooled data
approach. Uncertainty of parameter estimates was determined
by bootstrapping, sampling single measurements randomly
with replacement within each experiment (N5300). Uncertainty
of the final PK model used for predictions and for driving the PD
model was generated based on Monte Carlo sampling from the
parameter distributions obtained from bootstrapping, and from
additional parameter uncertainties defined in Table 1. In addi-
tion to uncertainty with respect to parameter values, model pre-
dictions also incorporate the effect of uncertainty resulting from
the model’s residual variability (Supplementary Text S2).
Numeric analyses were performed in MATLAB (R2014a; The
MathWorks, Natick, MA). Specifically, the Matlab function fmin-
search was used for solving the optimization problems encoun-
tered during parameter estimation. The Matlab model code is
provided in the Supplementary Model Code files. The analyti-
cal solution used in the observation model was derived in Math-
ematica 10 (Wolfram Research, Champaign, IL).
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RESULTS
PK models for only ticagrelor or MEDI2452
Before the combined ticagrelor-MEDI2452 interaction model
could be set up, two independent PK models were derived
for the separate administration of ticagrelor in the mouse
and of MEDI2452 in the rat. The details of these models
are described in Supplementary Text S2, Supplementary
Figure S1, and Supplementary Figure S2. We found that
ticagrelor (and TAM) follows two-compartment kinetics in
the absence of MEDI2452, and that MEDI2452 kinetics in
Figure 1 Designs of validation studies 1 to 4. Mice were given ticagrelor as an i.v. infusion during 20 minutes. Immediately after the ticagrelor
infusion, an i.v. bolus dose of MEDI2452 or vehicle was given. Terminal blood samples for plasma exposure of ticagrelor and MEDI2452 were
collected at various time-points. For study design 3, gray circles indicate blood samples from a separate pharmacokinetic experiment.
Table 1 Model parameters
Name Unit Value Estimated value Uncertainty Explanation
f – 0.0020 0.0020 (not estimated) 0.0012, 0.0028a Fraction unbound ticagrelor (internal data, n538)
kon nM
21 3 min21 0.14 0.11 0.078, 0.122b Second-order rate constant. Initial point estimate
obtained from different estimates of the rate
constants of the similarly sized ligands
methotrexate, dabigatran, and topotecan.8,17,20,27
Kd nM 0.02 0.02 (not estimated) 0.013, 0.029
c Affinity of MEDI2452 for ticagrelor and TAM.6
Clmet L 3 min
21 3 kg21 0.012 0.0080 0.0077, 0.0083b TAM-specific ticagrelor clearance
Cl L 3 min21 3 kg21 0.058 0.022 0.019, 0.025b Remaining ticagrelor clearance
V1 L 3 kg
21 1.63 1.12 0.95, 1.18b Initial estimate obtained
by V1,Tica 2 VMEDI24525 1.68–0.05 L 3 kg
21
Cld L 3 min
21 3 kg21 0.042 0.041 0.050, 0.066b Ticagrelor intercompartmental clearance
V2 L 3 kg
21 1.8 1.8 1.32, 1.88b Ticagrelor volume of second compartment
V L 3 kg21 0.05 0.05 (not estimated) – MED2452 (central compartment) volume of distribution.
Standard plasma volume.
Clf L 3 min
21 3 kg21 0.0030 0.0025 0.0024, 0.0026b MED2452 Cl. Initial estimate scaled value from
rat (0.0048 L 3 min21 3 kg21) adjusted
to 60% to match data.
Clfast L 3 min
21 3 kg21 10 10 (not estimated) – Rapid compared to other clearances in the system
r2tica nM 3 nM 0.076 0.064, 0.081
b
r2TAM nM 3 nM 0.080 0.076, 0.087
b
r2MEDI nM 3 nM 0.28 0.26, 0.31
b
r2freetica nM 3 nM 0.042 0.039, 0.045
b
r2freeTAM nM 3 nM 0.060 0.057, 0.069
b
TAM, ticagrelor active metabolite; Tica, ticagrelor.
aFifth and 95th percentiles obtained from internal data (n538). bFifth and 95th percentiles obtained from bootstrapping. c95% confidence interval.6
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the absence of ticagrelor was adequately described using a
one-compartment model during the timescale of interest.
This timescale was dictated by the experiments in which
both compounds were administered and occurred over 80
minutes after drug dosing. The parameters of the rat
MEDI2452 model were furthermore adjusted based on allo-
metric scaling and a priori knowledge of mouse plasma vol-
ume to describe the presumed kinetics in the mouse
(Supplementary Text S2).
A combined ticagrelor-MEDI2452 PK model
A combined ticagrelor-MEDI2452 PK model was hypothe-
sized by integrating the independently derived models for
the respective compounds. To this end, assumptions were
required with respect to the reconciliation of compartment
structures of the two independent models and with respect
to certain kinetic matters brought to the fore by the model
integration.
Because the central compartment of the independent
MEDI2452 model equaled the mouse plasma volume, and
because the larger central compartment of the independent
ticagrelor and TAM model could be reasonably expected to
contain the plasma volume, we assumed the central com-
partment of the independent ticagrelor and TAM model to
be divided into two subcompartments for the hypothesized
combined model. A plasma compartment that is identical to
the central compartment of independent MEDI2452 model,
with the previously introduced volume V (Supplementary
Text S2), and a compartment representing tissue rapidly
exchanging with plasma, with the new volume V1, now rep-
resenting the remainder of the previous ticagrelor and TAM
central compartment. Thus, V accommodates all com-
pounds, whereas V1 is only for ticagrelor and TAM. The
peripheral compartment with volume V2 of the independent
ticagrelor and TAM model (Supplementary Text S2) was
kept unchanged.
We further assumed that: (I) binding and unbinding of
ticagrelor and TAM to plasma protein is fast (i.e., the reac-
tion is considered to reach equilibrium instantaneously);
(II) distribution between V and V1 also is fast in the above
sense; (III) the ticagrelor-MEDI2452 complex is cleared at
the same rate as MEDI2452; and (IV) the kinetics of TAM
is governed by the same principles as ticagrelor (i.e., the
equations are structurally equivalent, using the same
parameters as for ticagrelor). Assumption (I) is a standard
assumption within PK modeling because this equilibrium
typically is reached on a timescale of seconds, and it is jus-
tified in our case in which the other dynamics occur on a
timescale of minutes. Assumption (II) is reasonable
because we were not able to improve the separate ticagre-
lor PK model by adding a third compartment. Assumption
(III) is natural if no other information is available and it has
been used in similar modeling situations.13–15 Regarding
assumption (IV), all aspects of TAM kinetics have not been
Figure 2 Schematic illustration of the combined ticagrelor-MEDI2452 pharmacokinetic-model. Reactions assumed to equilibrate instan-
taneously are indicated by double arrows. Input to the system (ticagrelor and MEDI2452) are shown as dashed arrows. The rapid equi-
libriums of free and protein-bound ticagrelor and ticagrelor active metabolite (TAM) are depicted by encapsulated entities. The fractions
of free ticagrelor and TAM within these entities are determined by the parameter f. The total contents of free and protein-bound ticagre-
lor and TAM in the plasma compartment (V) are cleared at the rate Cl, and ticagrelor is additionally being metabolized to TAM at the
rate Clmet. The total content of the encapsulated ticagrelor entity may furthermore distribute instantaneously to one peripheral compart-
ment (V1), and more slowly, with the intercompartmental clearance Cld, to another (V2). Free ticagrelor and TAM in the plasma com-
partment can reversibly bind to free MEDI2452 with the rate kon, forming complexes with dissociation constant Kd. Both the complexes
and free MEDI2452 are cleared at the rate Clf.
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investigated, but it is known that the affinities of both
MEDI2452 and P2Y12 for TAM,
6 (data on file) are highly
similar to the corresponding affinities for ticagrelor.6,16 The
possibility of target-mediated drug disposition was excluded
from the model according to the discussion in Supplemen-
tary Text S2.
The model is illustrated in Figure 2. It is defined by the
following equations:
V3TicaVðtÞ052Clfast3

TicaVðtÞ2TicaV1ðtÞ

2Cld3

TicaVðtÞ2TicaV2ðtÞ

2 V3kon

f3TicaVðtÞ3FabV ðtÞ2Kd3FabTicaVðtÞ

2Clmet3TicaVðtÞ2Cl3TicaVðtÞ1TicaInputðtÞ;
(1)
V13TicaV1 tð Þ05Clfast3

TicaVðtÞ2TicaV1 tð Þ

; (2)
V23TicaV2ðtÞ05Cld3

TicaVðtÞ2TicaV2ðtÞ

; (3)
V3TamVðtÞ052Clfast3

TamVðtÞ2TamV1ðtÞ

2Cld3

TamVðtÞ2TamV2ðtÞ

2 V3kon

f3TamVðtÞ3FabV ðtÞ2Kd3FabTamVðtÞ

1Clmet3TicaVðtÞ2Cl3TamVðtÞ;
(4)
V13TamV1 tð Þ05Clfast3

TamVðtÞ2TamV1 tð Þ

; (5)
V23TamV2ðtÞ05Cld3

TamVðtÞ2TamV2ðtÞ

; (6)
V3FabVðtÞ052 V3kon

f3TicaVðtÞ3FabVðtÞ2Kd3FabTicaVðtÞ

2 V3kon

f3TamV ðtÞ3FabVðtÞ2Kd3FabTamVðtÞ

2Clf3FabVðtÞ1FabInputðtÞ;
(7)
V3FabTicaVðtÞ05V3kon

f3TicaVðtÞ3FabV ðtÞ2Kd3FabTicaVðtÞ

2Clf3FabTicaVðtÞ;
(8)
V3FabTamVðtÞ05V3kon

f3TamVðtÞ3FabVðtÞ2Kd3FabTamVðtÞ

2Clf3FabTamVðtÞ;
(9)
where the state variables TicaV(t), TicaV1(t), TicaV2(t),
TamV(t), TamV1(t), and TamV2(t) refer to the time-dependent
concentrations of free and protein-bound (not including
MEDI2452) ticagrelor and TAM in V, V1, and V2, respectively,
where FabV(t) refers to MEDI2452 concentration in V, and
where FabTicaV(t) and FabTamV(t) refer to the ticagrelor-
MEDI2452, and TAM-MEDI2452 complexes in V. Values of the
parameters, and their justifications, are reported in Table 1.
Observation model
The reactions in which ticagrelor and TAM form complexes
with MEDI2452 do, in general, never fully reach their equilibria
in the in vivo system. This is due to the continuously ongoing
clearance and redistribution of the interacting species, which
interferes with the processes of reaching the equilibria. When
blood samples are collected, however, physiological reactions,
like clearances and intercompartmental distribution, are inter-
rupted, and there is sufficient time available for reaching the
equilibria before the bioanalysis of the sample content is com-
plete. Because of this, a model of the dynamic process taking
place in vitro is required in addition to the original model of the
in vivo system. Such an observation model can mathemati-
cally be constructed by setting the values of all clearance
parameters to zero, reflecting the in vitro conditions of the bio-
analysis, and then compute the closed-form analytical solution
for the equilibria (Supplementary Text S2). The use of the
observation model is critical for distinguishing between actual
levels of free ticagrelor and TAM, and of measured values
(Supplementary Figure S3). Specifically, the observed con-
centrations of free ticagrelor and free TAM are less than the
concentrations of free ticagrelor and free TAM in the in vivo
system. For free levels of MEDI2452, which is present in
larger concentrations compared to free ticagrelor and TAM,
the difference of using the observation model becomes
marginal.
The hypothesized model explains observed data from
four separate studies
The model was validated on experimental data from study
1 to 4, comprising different dosing and sampling schedules
(Figure 1). By a reduction (40%) of the allometrically
scaled MEDI2452 clearance (corresponding to scaling rat-
mouse with exponent 1 and not 0.75), and without chang-
ing any other parameter value, we could reasonably well
simulate all the qualitative characteristics of the observed
data (Figure 3), as well as many of the quantitative charac-
teristics. For studies 1 to 3, the predicted time profiles of
plasma levels of total ticagrelor, total TAM, and free
MEDI2452 were generally in accordance with data,
although there was some underprediction of total ticagrelor
and total TAM in the absence of MEDI2452, especially in
study 3. For study 4, both model and data displayed
increasing levels of total ticagrelor, total TAM, and free
MEDI2452, as a function of dose, as well as decreasing
levels of free ticagrelor and free TAM as a function of dose.
Although the model performed reasonably well for total and
free ticagrelor and TAM in study 4, there was a tendency to
underpredict free ticagrelor and free TAM and at lower
doses there was an overprediction of free MEDI2452.
The validation data were subsequently used to refine the
model by reestimation of some of its parameters (Table 1).
As shown in Figure 3, the refined model improved the fit to
data in general, including– to us – the particularly important
levels of free ticagrelor and free TAM. A residual plot for the
refined model is presented in Supplementary Figure S4.
Ticagrelor is not likely to be fully recycled
When ticagrelor-bound or TAM-bound MEDI2452 is elimi-
nated in the kidneys, it is currently not known if ticagrelor
and TAM are eliminated, recycled, or a combination thereof.
Fabs are, however, generally cleared through the kidneys
and elimination is faster than for immunoglobulin G (IgG).17
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Figure 3 Model validation and refinement. Observed total and free ticagrelor (tica) in plasma are shown as red circles (when
MEDI2452 has been coadministrated) or red stars (without MEDI2452), observed total and free ticagrelor active metabolite (TAM) in
plasma as green squares (with MEDI2452) or green diamonds (without MEDI2452), and observed free MEDI2452 in plasma as blue
triangles. Model simulations of ticagrelor, TAM, and MEDI2452 are shown in red, green, and blue lines, respectively. Dashed lines indi-
cate the initially hypothesized model, and solid lines the refined model. LLOQ, lower limit of quantification.
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Our main hypothesis (assumption III) has therefore been
that both compounds are eliminated intact via the urine as a
complex together with MEDI2452, and the model based on
this assumption fits data reasonably well. To challenge this
assumption we instead assumed that a fraction r of cleared
ticagrelor and TAM is recycled. This was implemented in the
model by adding the terms r3Clf3FabTicaV tð Þ and r3Clf3
FabTamV tð Þ to the right-hand sides of Eq. (1) and (4),
respectively. For the values 0.25, 0.5, and 1 of the recycling
fraction r , the previously refined model parameters were
then reestimated. The resulting negative log-likelihood values
(174, 287, and 613) show that the model becomes increas-
ingly inferior for higher degrees of recycling. These values
should also be compared to the model completely lacking
recycling, whose negative log-likelihood value is 95 and
thereby remains the best model. The same conclusion also
follows from inspecting the model simulations in Figure 4;
whereas the model of total ticagrelor and total TAM are only
slightly worsened by the successive increase in the recycled
fraction, free levels of ticagrelor and TAM are worse, and
free MEDI2452 levels are drastically impaired.
Predicted total ticagrelor plus TAM and free ticagrelor
plus TAM in plasma show opposite response after
administration of MEDI2452
The refined model was subsequently used to predict the
dynamics of both observed and unobserved variables in
studies 1 to 4. For these predictions, the effects of both
parameter uncertainties and residual variability were taken
into account. This was done by Monte Carlo simulations in
which parameter values were sampled according to the
uncertainties derived from formal parameter estimation or
from uncertainties reported in literature. Figure 5 shows
simulations of total ticagrelor plus TAM, free MEDI2452,
and free ticagrelor plus TAM in V in response to coadminis-
tration of ticagrelor with either MEDI2452 or vehicle. For all
designs, total ticagrelor plus TAM and free ticagrelor plus
TAM in plasma show opposite response after administration
of MEDI2452, with total levels rising while free levels drop.
We also note that the levels of free ticagrelor plus TAM
after administration of MEDI2452 always remain below the
corresponding levels for the vehicle groups during the 100
minutes of the experiments. Importantly, the predictions in
Figure 5 were computed for the in vivo levels of free tica-
grelor plus TAM (i.e., the observation model was not used).
As previously explained, and illustrated in Supplementary
Figure S3, true in vivo levels and measured levels in ex
vivo samples of ticagrelor and TAM may differ significantly.
The PK model can drive the PD response using a
standard turnover model
Inhibition of platelet aggregation stimulated by ADP is a com-
monly used PD marker for P2Y12 receptor antagonists, both in
animals and in the clinic. The predicted levels of free ticagrelor
plus TAM were therefore used to drive a simple turnover
model describing the dynamics of platelet aggregation, as
described in detail in Supplementary Text S2. As seen in
Figure 6, the combined ticagrelor-MEDI2452 PK model
extended with a platelet aggregation PD model can describe
experimental data in a quite satisfactory way. A residual plot
for the PD model is provided in Supplementary Figure S5.
DISCUSSION
Mathematical PK models accounting for the effects of an
interfering antidote are scarce in the literature, indicating that
this kind of modeling remains largely unexplored. A few exist-
ing examples include modeling of so-called inverse targeting
strategies, in which antidrug antibodies are administered to
reduce systemic drug toxicities.13–15,18 There are similarities
between our model and the class of target-mediated drug
disposition models19–21 in the sense that it mechanistically
accounts for the buffering interaction of ticagrelor (and TAM)
with another molecular species. In our case, the interacting
entity is not the drug target, but instead an antidote. Like
the target-mediated drug disposition models, which in addi-
tion to the interaction itself also includes other necessary
aspects of the target dynamics, such as its turnover, our
model also includes the parts of the antidote dynamics that
are not directly affecting its interaction with ticagrelor (i.e., its
distribution and clearance). However, in contrast to our model
in which the dynamic aspect of ticagrelor-antidote binding is
preserved, target-mediated drug disposition models are
frequently simplified according to the rapid-binding
assumption.22
As a step toward validating the model, it was compared to
completely fresh data that had not been used for setting up
the model. Strictly speaking, models can never be validated
but the confidence in a model gradually increases as it suc-
cessfully predicts new experiments and repeatedly withstands
attempts of falsification.23 Given a minor change in the param-
eter value for MEDI2452 clearance, the model successfully
described the qualitative characteristics of the experimental
data of total and free ticagrelor and TAM, and free MEDI2452,
in four different studies. Many of the quantitative characteris-
tics were also acceptably well described. Considering the
simplicity of allometric scaling it is fully reasonable that a
parameter value not derived from mouse data would require a
slight final adjustment. By additionally reestimating some of
the model parameters, allowing the validation data to inform
the inference, an even better description of the data with
respect to the quantitative details was possible. Moreover, the
successful application of free level predictions to platelet
aggregation data further contributes to validating the com-
bined ticagrelor-MEDI2452 PK model. The overall outcome of
the model validation and refinement is encouraging and sug-
gests that the principles and assumptions underlying the
model are sound and that the model has true predictive capa-
bilities. However, there are still possible improvements to be
made, for instance, by considering a full nonlinear mixed
effects approach.24,25
A na€ıve analysis of the data may suggest that administra-
tion of MEDI2452 is a counterproductive strategy for neu-
tralizing the effects of ticagrelor because it results in a
rapid increase by more than an order of magnitude in the
total plasma levels of both ticagrelor and TAM. Similar
observations of rapidly increasing total levels after antidote
administration have been made for colchicine,26
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dabigatran,27 and rivaroxaban.12 However, model simula-
tions show that, despite the large increases in total plasma
ticagrelor levels, the free levels in fact display an opposite
response after administration of MEDI2452. Reasoning
about the structure and parameter values of the model
helps to explain the relationship between total and free
plasma ticagrelor. Because the volume of distribution for
ticagrelor is much larger compared to MEDI2452 (i.e.,
V1V11V2  V ), free ticagrelor that is bound by
MEDI2452 is rapidly replenished from V1, and on a slower
timescale also from V2. Thus, MEDI2452 is effectively act-
ing like a buffer for ticagrelor in the plasma compartment,
causing a substantial accumulation of total ticagrelor in the
plasma. A similar explanation can be used for understand-
ing the increase in total TAM. Moreover, if the molar dose
of MEDI2452 is comparable to or larger than the total
amount of ticagrelor and TAM in all three compartments at
the time of dosing, MEDI2452 will bind sufficient ticagrelor
and TAM to induce a significant reduction of their free levels
in all compartments, including plasma. Although some of
the qualitative behaviors of the combined ticagrelor-
MEDI2452 PK can be understood from pure reasoning like
above, the quantitative details are harder to grasp by intu-
ition because of the nonlinear interaction of ticagrelor and
MEDI2452, the delayed distribution of ticagrelor to V2, and
the metabolism of ticagrelor to TAM, which, in turn, also
competes for MEDI2452.
The ability to predict the plasma concentrations of free
ticagrelor and free TAM are the key results from the present
work. Knowledge about these levels is important because
they drive the PD response and therefore also predict the
efficacy of MEDI2452. Having access to a trustworthy
model is advantageous because it can be used as a com-
plement or an alternative to experimental observations.20,21
Although model simulations of the measured free ticagrelor
and TAM have been validated, at least to some degree, all
simulations of the actual free levels in vivo (Figure 5) are
untested predictions. In fact, these predictions are not only
untested but also untestable given the current experimental
procedure of measuring free levels of ticagrelor and TAM.
Mathematical modeling is therefore a necessity for unravel-
ing the details of the combined ticagrelor-MED2452 PK.
The values of the model parameters—both the parameters
estimated in the present work and those taken from
literature—are uncertain to some degree, and, as a conse-
quence, the model predictions are uncertain too. Providing a
measure of uncertainty for the model state variables is often
more interesting than the parameter uncertainties, but,
unfortunately, also often overlooked. We have showed that,
despite the parameter uncertainty, the behavior of the model
predictions is relatively well defined. In addition to uncertain-
ties in parameter values, there may be uncertainties with
respect to the model structure. It is, for instance, not known
what happens to ticagrelor and TAM when ticagrelor-bound
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Figure 5 Prediction based on the validated model for studies 1 to 4. Curves represent the simulated 5th and 95th percentiles of the
sum of free ticagrelor and free ticagrelor active metabolite (TAM) in plasma (purple dashed-dotted lines), sum of total ticagrelor and
TAM in plasma (red solid lines), and free MEDI2452 (MEDI) in plasma (blue dashed line). The dotted lines indicate the scenario with
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or TAM-bound MEDI2452 is being eliminated, but because
of the presumed renal elimination we assumed that no recy-
cling occurs. There are examples of other modeling studies
that have considered both full recycling of antibody
ligands14,15 and partial (25%) recycling of Fab ligands.14 We
showed that model behavior was highly sensitive to introduc-
ing a recycling mechanism, and that the corresponding alter-
native predictions successively became more and more
difficult to reconcile with experimental data as the degree of
recycling was increased from 0% to 100%. Thus, the model-
ing supports the view that, in the mouse, when MEDI2452 is
eliminated, potential ticagrelor or TAM bound to MEDI2452
is not primarily recycled to the plasma (but eliminated
together with MEDI2452), although we would not exclude
that a smaller fraction may be. This is an important finding
as it constitutes a possible scenario in the extrapolation to
humans. The analysis of potential recycling rests on the
notion that the clearance of MEDI2452 in the combined PK
model represents elimination and not distribution. It was
therefore crucial to ensure that the rapid phase of the sepa-
rate MEDI2452 PK model was due to elimination, before
reducing the initial two-compartment model to a one-
compartment model (Supplementary Text S2).
The proposed model is a good starting point for scaling to
model the PK of other species, including humans, and for
expansion to a population model. Hence, we anticipate it to
be valuable in the future clinical development of MEDI2452.
Conflict of Interest/Disclosure. The authors declared no
conflict of interest.
Author Contributions: J.A., S.N., and P.G. wrote the manu-
script. J.A., S.P., S.N., and P.G. designed the research. S.P., A-
S.S., A.J., S.Maq., S.Mad., and J.G. performed the research.
J.A., M.P., S.N., and P.G. analyzed the data.
1. Van Giezen, J.J. et al. Ticagrelor binds to human P2Y(12) independently from ADP
but antagonizes ADP-induced receptor signaling and platelet aggregation. J. Thromb.
Haemost. 7, 1556–1565 (2009).
2. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syn-
dromes. N. Engl. J. Med. 361, 1045–1057 (2009).
3. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coro-
nary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494–502 (2001).
4. Wiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syn-
dromes. N. Engl. J. Med. 357, 2001–2015 (2007).
5. Bonaca, M.P. et al. Long-term use of ticagrelor in patients with prior myocardial
infarction. N. Engl. J. Med. 372, 1791–1800 (2015).
6. Buchanan, A. et al. Structural and functional characterization of a specific antidote for
ticagrelor. Blood 125, 3484–3490 (2015).
7. Dolgin, E. Antidotes progress for new oral clotbusters. Nat. Biotechnol. 33, 117–118
(2015).
8. Schiele, F. et al. A specific antidote for dabigatran: functional and structural charac-
terization. Blood 121, 3554–3562 (2013).
9. Glund, S. et al. A randomised study in healthy volunteers to investigate the safety,
tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Thromb. Haemost. 113, 943–951 (2015).
10. Glund, S. et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of
the anticoagulant effect of dabigatran in healthy male volunteers: a randomised,
placebo-controlled, double-blind phase 1 trial. Lancet 386, 680–690 (2015).
11. Pollack, C.V. Jr. et al. Idarucizumab for dabigatran reversal. N. Engl. J. Med. 373,
511–520 (2015).
12. Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect
inhibitors of coagulation factor Xa. Nat. Med. 19, 446–451 (2013).
13. Balthasar, J. & Fung, H.L. Utilization of antidrug antibody fragments for the optimiza-
tion of intraperitoneal drug therapy: studies using digoxin as a model drug. J. Phar-
macol. Exp. Ther. 268, 734–739 (1994).
14. Lobo, E.D., Soda, D.M. & Balthasar, J.P. Application of pharmacokinetic-
pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-
methotrexate antibodies in mice. J. Pharm. Sci. 92, 1665–1676 (2003).
15. Shah, D.K. & Balthasar, J.P. PK/TD modeling for prediction of the effects of 8C2, an anti-
topotecan mAb, on topotecan-induced toxicity in mice. Int. J. Pharm. 465, 228–238 (2014).
16. Springthorpe, B. et al. From ATP to AZD6140: the discovery of an orally active
reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg. Med.
Chem. Lett. 17, 6013–6018 (2007).
17. King, D.J. Applications and Engineering of Monoclonal Antibodies (Taylor & Francis
Ltd, London, 1988).
18. Balthasar, J.P. & Fung, H.L. Inverse targeting of peritoneal tumors: selective altera-
tion of the disposition of methotrexate through the use of anti-methotrexate antibodies
and antibody fragments. J. Pharm. Sci. 85, 1035–1043 (1996).
19. Mager, D.E. & Jusko, W.J. General pharmacokinetic model for drugs exhibiting target-
mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28, 507–532 (2001).
20. Xiao, J.J. et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m
and hepcidin in cynomolgus monkeys. AAPS J. 12, 646–657 (2010).
21. Tang, C. & Prueksaritanont, T. Theoretical analysis of interplay of therapeutic protein
drug and circulating soluble target: temporal profiles of ‘free’ and ‘total’ drug and tar-
get. Pharm. Res. 28, 2447–2457 (2011).
22. Marathe, A., Krzyzanski, W. & Mager, D.E. Numerical validation and properties of a
rapid binding approximation of a target-mediated drug disposition pharmacokinetic
model. J. Pharmacokinet. Pharmacodyn. 36, 199–219 (2009).
23. Almquist, J., Cvijovic, M., Hatzimanikatis, V., Nielsen, J. & Jirstrand, M. Kinetic mod-
els in industrial biotechnology – improving cell factory performance. Metab. Eng. 24,
38–60 (2014).
24. Bonate, P. Pharmacokinetic-Pharmacodynamic Modeling and Simulation (Springer,
New York, 2006).
25. Almquist, J., Leander, J. & Jirstrand, M. Using sensitivity equations for computing gra-
dients of the FOCE and FOCEI approximations to the population likelihood. J. Phar-
macokinet. Pharmacodyn. 42, 191–209 (2015).
26. Sabouraud, A.E., Urtizberea, M., Cano, N.J., Grandgeorge, M., Rouzioux, J.M. &
Scherrmann, J.M. Colchicine-specific Fab fragments alter colchicine disposition in rab-
bits. J. Pharmacol. Exp. Ther. 260, 1214–1219 (1992).
27. van Ryn, J., Litzenburger, T., Gan, G., Coble, K. & Schurer, J. In vitro characteriza-
tion, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced
bleeding in rats by a specific antibody fragment antidote to dabigatran. 54th ASH
Annual Meeting and Exposition, Atlanta, GA, 8–11 December 2012. Abstract 3418.
VC 2016 The Authors CPT: Pharmacometrics & Systems
Pharmacology published by Wiley Periodicals, Inc. on
behalf of American Society for Clinical Pharmacology and
Therapeutics. This is an open access article under the
terms of the Creative Commons Attribution-
NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original
work is properly cited and is not used for commercial
purposes.
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website
(http://www.wileyonlinelibrary.com/psp4)
Pharmacokinetics of Ticagrelor and MEDI2452
Almquist et al.
323
www.wileyonlinelibrary/psp4
